...
首页> 外文期刊>Journal of experimental therapeutics & oncology >Expression of death decoy receptor-3 (DcR3) in human breast cancer and its functional effects on breast cancer cells in vitro.
【24h】

Expression of death decoy receptor-3 (DcR3) in human breast cancer and its functional effects on breast cancer cells in vitro.

机译:死亡诱饵受体-3(DCR3)在人乳腺癌中的表达及其对体外乳腺癌细胞的功能作用。

获取原文
获取原文并翻译 | 示例

摘要

BACKGROUND: Death Decoy Receptor-3 (DcR3), otherwise known as tumour necrosis factor receptor superfamily member 6b, is suggested to be involved in the progression and immune evasion of malignant tumours. Its ligands include FASL and LIGHT (Tumour necrosis factor ligand superfamily member 14). DcR3 has been found to be amplified in certain solid tumours. However, its role in breast tumours remains unclear. In the present study, we examined the role played by DcR3 in MCF7 and MDA-MB-231 cell lines. MATERIALS AND METHODS: The expression of DcR3 was examined in MCF7 and MDA-MB-231 cell lines using immunocytochemical staining and RT-PCR. Anti-DcR3 hammerhead ribozyme transgenes were constructed and transfected into cells to create DcR3 knock-down cell sublines. The biological impact of modifying DcR3 expression in breast cancer cells was evaluated using a variety of in vitro assays, including growth, adhesion, migration and invasion models. RESULTS: MCF7 and MDA-MB-231 cells, usually expressing DcR3, were transfected with the anti-DcR3 ribozyme transgene. Stable transfectants containing the DcR3 ribozyme transgene (MCF7DcR3KO, MDA-MB-231DcR3KO) displayed a reduction of DcR3 expression at mRNA and protein levels. DcR3 knockdown in MCF7 cells was found to significantly reduce invasive capacity compared to pEF6 control cell lines (30.78 +/- 6.40 vs.151.67 +/- 17.67 P < 0.001). The rate of migration in MCF7DcR3KO was significantly lower than MCF7pEF6 (P < 0.001). In contrast, no such significant differences was seen between MDA-MB-231DcR3KO and MDA-MB-231pEF6. CONCLUSION: Suppressing DcR3 expression was found to have an inhibitory effect on cellular invasion and migration in MCF7 breast cancer cells. This suggests that the invasion and migration capacity of this breast cancer cell line may, at least partly, depend on DcR3. DcR3 may be regarded as a negative regulator for aggressiveness during the development and progression of certain types of breast cancer.
机译:背景:死亡诱饵受体-3(DCR3),否则称为肿瘤坏死因子受体超家族成员6b,建议参与恶性肿瘤的进展和免疫逃避。其配体包括FasL和光(肿瘤坏死因子配体超家族成员14)。已发现DCR3在某些实体瘤中被扩增。然而,它在乳腺肿瘤中的作用仍不清楚。在本研究中,我们检查了DCR3在MCF7和MDA-MB-231细胞系中发挥的作用。材料和方法:使用免疫细胞化学染色和RT-PCR在MCF7和MDA-MB-231细胞系中检测DCR3的表达。构建抗DCR3锤头核酶转基因并将其转染到细胞中以产生DCR3敲除细胞载体。使用各种体外测定评估修饰DCR3表达在乳腺癌细胞中的生物学影响,包括生长,粘附,迁移和侵袭模型。结果:MCF7和MDA-MB-231细胞,通常表达DCR3,用抗DCR3核酶转基因转染。含有DCR3核酶转基因(MCF7DCR3KO,MDA-MB-231DCR3KO)的稳定转染剂显示了mRNA和蛋白质水平的DCR3表达的还原。与PEF6控制细胞系相比,发现MCF7细胞中的DCR3敲低明显减少侵入性容量(30.78 +/- 6.40 Vs.151.67 +/- 17.67 p <0.001)。 MCF7DCR3KO中的迁移率明显低于MCF7PEF6(P <0.001)。相反,在MDA-MB-231DCR3KO和MDA-MB-231PEF6之间没有看到这种显着差异。结论:发现抑制DCR3表达对MCF7乳腺癌细胞的细胞侵袭和迁移具有抑制作用。这表明该乳腺癌细胞系的侵袭和迁移能力至少部分依赖于DCR3。 DCR3可被视为在某些类型的乳腺癌的开发和进展过程中进行攻击性的负调节因子。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号